Loading company…
7 Hills Pharma
Private7 Hills Pharma Receives $4.7MM Grant to Advance First-in-class Cell/Gene Therapy Technology into the Clinic
Pharma
- Founded
- 2015Source: [SRC]
- Headquarters
- Houston, TXSource: [SRC]
- Headcount
- 10Source: [SRC]
- Stage
- Late stage
- Sector
- Healthcare
$4.7MSource: [SRC]Raised (recorded)
UndisclosedSource: [SRC]Last valuation
Overview
HOUSTON, June 03, 2024 (GLOBE NEWSWIRE) -- 7 Hills Pharma Inc. (“7 Hills” or “7HP”), a clinical-stage pharma company leveraging a novel mechanism of action to safely enhance the effectiveness of cancer immunotherapies, was awarded $4.7 million from the Cancer Prevention and Research Institute of Texas (CPRIT) to support its cell/gene therapy (CGT) development program. This grant will allow 7 Hills to advance 7HP935, the Company’s lead first-in-class small molecule to augment CGT, through a Phase I clinical trial. 7HP’s CGT program has previously been awarded over $3.2 million via multiple awards from the National Heart, Lung, and Blood Institute, including STTR grants R41HL129612 and R42HL129612, and Catalyze grant R33HL161778.
Funding rounds
No rounds recorded yet for 7 Hills Pharma.
Add a funding roundInvestors
No investors recorded yet for 7 Hills Pharma.
Add an investorPeople
No people recorded yet for 7 Hills Pharma.
Add a team memberAcquisitions
7 Hills Pharma has no recorded acquisitions.
Add an acquisitionExits
Still private — no exit on record.
Record an exitDiversity investments
No diversity signals recorded yet for 7 Hills Pharma.
Add diversity data